SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059099
Filing Date
2024-05-14
Accepted
2024-05-14 08:00:52
Documents
62
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q pyxs-20240331.htm   iXBRL 10-Q 1772821
2 EX-31.1 pyxs-ex31_1.htm EX-31.1 14389
3 EX-31.2 pyxs-ex31_2.htm EX-31.2 14394
4 EX-32.1 pyxs-ex32_1.htm EX-32.1 8568
5 EX-32.2 pyxs-ex32_2.htm EX-32.2 7925
6 GRAPHIC img32419210_0.jpg GRAPHIC 75484
  Complete submission text file 0000950170-24-059099.txt   7066073

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20240331.xsd EX-101.SCH 1357617
65 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20240331_htm.xml XML 786803
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

IRS No.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40881 | Film No.: 24941503
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)